Radiopharm Theranostics Limited
RADXNASDAQHealthcare● Active
$4.21
$-0.11(-2.55%)
Market Cap$5423322
P/E Ratio—
52W High$16.25
52W Low$3.62
Radiopharm Theranostics Limited（RADX）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · RADX · 截至 2026-06-09
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-06 | 2024-06 | 2023-06 | 2022-06 |
|---|---|---|---|---|
| Revenue | ||||
| Revenue | $3.63M | $0.30M | $0.29M | $0.01M |
| Cost of Revenue | $3.59M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $0.04M | $0.30M | $0.29M | $0.01M |
| Gross Margin %(computed) | 1.08% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | ||||
| R&D Expenses | $27.52M | $17.56M | $13.80M | $4.12M |
| G&A Expenses | $16.53M | $15.22M | $13.02M | $10.85M |
| Total Operating Expenses | $38.21M | $36.92M | $34.80M | $19.93M |
| Operating Income | ($38.17M) | ($36.62M) | ($34.51M) | ($19.92M) |
| Operating Margin %(computed) | — | — | — | — |
| Interest Income | $0.89M | $0.05M | $0.15M | $0.00M |
| Interest Expense | $0.07M | $0.64M | $0.09M | $9.35M |
| Income Before Tax | ($38.24M) | ($47.85M) | ($34.57M) | ($30.29M) |
| Income Tax Expense | $0.10M | $0.10M | $0.04M | $0.04M |
| Net Income | ($38.34M) | ($47.95M) | ($34.61M) | ($30.34M) |
| Net Margin %(computed) | — | — | — | — |
| Per Share & EBITDA | ||||
| EPS (Basic) | $-5.28 | $-36.00 | $-33.00 | $-29.76 |
| Wtd Avg Shares | 6.94M | 1.29M | 1.02M | 1.02M |
| EBITDA | ($38.17M) | ($44.08M) | ($31.19M) | ($17.96M) |
| EBITDA Margin %(computed) | — | — | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-09 · AUD · M
深入了解Radiopharm Theranostics Limited
关于Radiopharm Theranostics Limited（RADX）损益表
Radiopharm Theranostics Limited（RADX）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，RADX实现营收$0.00B，毛利润$0.00B（毛利率1.08%），净利润($0.04B)（净利率-1055.27%）。
常见问题
RADX · 4 问Radiopharm Theranostics Limited（RADX）2025财年营收为$0.00B，同比up1114.3%。
RADX revenueRADX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09